CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Germany's Gerresheimer prelim Q3 revenue rises on strong demand for drug delivery devices

By Reuters News


Overview

  • Germany pharma packaging provider's preliminary Q3 revenue rose 8% yr/yr to EUR 605 mln

  • Adjusted EBITDA for Q3 remained stable compared to prior year

  • Revenue growth driven by higher demand for drug delivery devices


Outlook

  • Gerresheimer expects a stronger Q4 2026 with further earnings improvement, in line with guidance

  • Company expects completion of Primary Packaging Plastics business sale in Q1 2027

  • Measures underway to improve capacity utilization and competitiveness in Tubular Glass business


Result Drivers

  • DRUG DELIVERY DEVICES - Co said rising demand for drug delivery devices drove revenue growth in Containment & Delivery Systems division

  • INVENTORY REDUCTION - Co said inventory reductions in Moulded Glass division lowered capacity utilization and negatively impacted adjusted EBITDA

  • DIVISION PERFORMANCE - Co said weaker performance in Tubular Glass Europe and Moulded Glass divisions contributed to lower adjusted EBITDA for 9M period


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 605 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 9 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Gerresheimer AG is €26.90, about 15.7% below its October 29 closing price of €31.90

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Oct 29 - Germany's Wacker Chemie's Q3 core profit nearly doubles on cost cuts; keeps outlook

  • Oct 29 - US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook

  • Oct 29 - Merck Q3 profit beats on Keytruda demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.